Advertisement

Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study

  • Neda SoleimaniEmail author
  • Akbar Vaseghi
  • Valentina Loconte
ORIGINAL ARTICLE
  • 25 Downloads

Abstract

Poliglusam nanoparticles are potential therapeutic agents for the treatment of cancer. In particular, their efficacy has been reported as delivery systems in breast cancer. The aim of this study is to propose a new immunotherapeutic strategy, using Poliglusam nanoparticles as activators of the human immune response. Poliglusam nanoparticles were synthesized and characterized using both dynamic light scattering and electron microscopy. Whilst, their effectiveness in immune stimulation and detection of apoptosis was evaluated by cytokine and TUNEL assays. Finally, the cytokines pattern in splenocytes revealed an increase in IFN-γ production. The results of cytotoxicity on 4 T1 cells show an increase in the mortality rate with respect to the control cell line. The rate of apoptosis induced by Poliglusam nanoparticles on 4 T1 mouse breast cancer cell line is about 45% higher compared to MCF-7 human cells line, revealing the natural tendency of Poliglusam in increasing the production of IFN-γ in cancer cells. At the state-of-art of the knowledge, very few information have been achieved on the immunological effects of Poliglusam. This work is one of the first studies for the identification of non-functionalized Poliglusam nanoparticles impact on breast cancer. Thus, their immunotherapeutic effect, combined with an anticancer drug, can be employed as potential effective drug for eliminating breast cancer cells in the future.

Keywords

Poliglusam Nanoparticles Breast cancer Immunotherapy and apoptosis 

Notes

Acknowledgements

The authors specially thank the professor Majid Sadeghizadeh and his laboratory for their kind help at Tarbiat Modares University in Tehran and Shahid Beheshti University.

Author Contributions

NS conceived the study. NS conducted the experiments and analyzed the results. NS and AV drafted the manuscript and made substantial contributions to the design of the study. NS and AV critically reviewed the manuscript and participated in data analysis. All the authors studied and approved the final manuscript.

Compliance with Ethical Standards

Ethical Issues

None to be declared.

Competing Interests

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Ajun W et al (2009) Preparation of aspirin and Probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym 75:566–574CrossRefGoogle Scholar
  2. 2.
    Anitha A et al (2011) Efficient water soluble O-carboxylmethyl chitosan Nanocarrier for the delivery of curcumin to Cancer cells. Carbohydr Polym 83:452–461CrossRefGoogle Scholar
  3. 3.
    Calvo P et al (1997) Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14:1431–1436CrossRefGoogle Scholar
  4. 4.
    Clarke MF et al (2006) Cancer stem cells--perspectives on current status and future directions: Aacr workshop on Cancer stem cells. Cancer Res 66:9339–9344CrossRefGoogle Scholar
  5. 5.
    Compton MM, Cidlowski JA (1986) Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology. 118:38–45CrossRefGoogle Scholar
  6. 6.
    Croisier F, Jerome C (2013) Chitosan-based biomaterial bioingeeniring. Eur Polym J 49:780–792CrossRefGoogle Scholar
  7. 7.
    Ebbinghaus C et al (2005) Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116:304–313CrossRefGoogle Scholar
  8. 8.
    García-Tuñón I et al (2007) Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 7:158CrossRefGoogle Scholar
  9. 9.
    Hosseinzadeh H et al (2012) Chitosan–Pluronic nanoparticles as Oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomedicine 7:1851–1863CrossRefGoogle Scholar
  10. 10.
    Ikeda H et al (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109CrossRefGoogle Scholar
  11. 11.
    Illum L et al (1994) Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11:1186–1189CrossRefGoogle Scholar
  12. 12.
    Kono T et al (1999) Cytotoxic activity of Pierisin, from the cabbage butterfly, Pieris Rapae, in various human Cancer cell lines. Cancer Lett 137:75–81CrossRefGoogle Scholar
  13. 13.
    Lee DY et al (2002) Chitosan and D-glucosamine induce expression of Th1 cytokine genes in porcine spleen cells. J Vet Med Sci 64:645–648CrossRefGoogle Scholar
  14. 14.
    Li GP et al (2009) Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol 6:45–50CrossRefGoogle Scholar
  15. 15.
    Me LT et al (2009) Cancer, chitosan and catalytic nucleic acids. J Pharm Pharmacol 61:3–12CrossRefGoogle Scholar
  16. 16.
    Moghaddam FA et al (2009) Preparation and in vitro evaluation of Mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine 5(2):208–15Google Scholar
  17. 17.
    Nunez C et al (2016) An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 97:34–50CrossRefGoogle Scholar
  18. 18.
    Peer D et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760CrossRefGoogle Scholar
  19. 19.
    Piccinini F et al (2017) Cell counting and viability assessment of 2D and 3D cell cultures: expected reliability of the trypan blue assay. Biol Proced Online 19:8CrossRefGoogle Scholar
  20. 20.
    Qi L et al (2004) Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res 339:2693–2700CrossRefGoogle Scholar
  21. 21.
    Ruiz-Ruiz C et al (2000) Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60:5673–5680Google Scholar
  22. 22.
    Sgadari C et al (1997) Mig, the Monokine induced by interferon-g, promotes tumor necrosis in vivo. Blood. 89:2635–2643Google Scholar
  23. 23.
    Stockler M et al (2000) Systematic reviews of chemotherapy and endocrine therapy in metastatic breast Cancer. Cancer Treat Rev 26:151–168CrossRefGoogle Scholar
  24. 24.
    Tang C et al (2007) Cancer stem cell: target for anti-Cancer therapy. FASEB J 21:3777–3785CrossRefGoogle Scholar
  25. 25.
    Windbichler GH et al (2000) Interferon-gamma in the first-line therapy of ovarian Cancer: a randomized phase iii trial. Br J Cancer 82:1138–1144CrossRefGoogle Scholar
  26. 26.
    Xu Y, Du Y (2003) Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 250:215–226CrossRefGoogle Scholar
  27. 27.
    Xu ZR et al (2004) Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res:2693–2700Google Scholar
  28. 28.
    Yousofi A et al (2012) Immunomodulatory effect of parsley (Petroselinum Crispum) essential oil on immune cells: mitogen-activated Splenocytes and peritoneal macrophages. Immunopharmacol Immunotoxicol 34:303–308CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Neda Soleimani
    • 1
    Email author
  • Akbar Vaseghi
    • 2
  • Valentina Loconte
    • 3
  1. 1.Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and BiotechnologyShahid Beheshti UniversityTehranIran
  2. 2.Department of Nanobiotechnology, faculty of Biological SciencesTarbiat Modares UniversityTehranIran
  3. 3.Department of Biomedical SciencesUniversity of PaduaPaduaItaly

Personalised recommendations